Trellis developed a proprietary technology for cloning antibodies, including calpurbatug (TRL1068), from human white blood cells. Human antibodies have a lower failure rate due to toxicity than any other drug class. Applied to infectious diseases, the technology has allowed discovery of antibodies from patients who have recovered from the disease. In addition to the lead biofilm disruption program, Trellis's pipeline includes antiviral antibodies (one of which is in a clinical trial) targeting major unmet medical needs.

Key Contact